Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor. (P versicolor)

PAEC General Hospital, Islamabad

Status and phase: Not yet enrolling; Phase 4

Conditions: Pityriasis Versicolor

Treatments: Drug: Luliconazole Cream 1%; Drug: Topical ketoconazole 2% cream

Study type: Interventional

Funder types: Other

Identifiers

NCT07333170

PAECIslamabad

Details and patient eligibility

About

Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.

Full description

Pityriasis versicolor is a superficial fungal infection caused by Malassezia species and is commonly treated with topical antifungal agents. Ketoconazole is a conventional treatment, while luliconazole is a newer topical antifungal with potent activity against fungal organisms. This randomized controlled trial is designed to compare the clinical and mycological efficacy, safety, and tolerability of topical luliconazole versus topical ketoconazole in patients diagnosed with pityriasis versicolor. Eligible participants will be randomly allocated into two treatment groups and followed for treatment response and adverse effects. The findings of this study may help determine a more effective topical treatment option for pityriasis versicolor.

Enrollment: 86 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients diagnosed with pityriasis versicolor.

Exclusion criteria

• Immunocompromised patients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

86 participants in 2 patient groups

Topical Luliconazole 1% cream

Experimental group

Description:

Participants will receive topical luliconazole 1% cream applied once daily to affected areas for the treatment of pityriasis versicolor.

Treatment:

Drug: Luliconazole Cream 1%

Topical ketoconazole 2% cream

Experimental group

Description:

Participants will receive topical ketoconazole 2% cream applied twice daily to affected areas for the treatment of pityriasis versicolor.

Treatment:

Drug: Topical ketoconazole 2% cream